AMPHASTAR PHARMACEUTICALS IN (AMPH) Fundamental Analysis & Valuation

NASDAQ:AMPH • US03209R1032

Current stock price

20.99 USD
-0.22 (-1.04%)
At close:
20.89 USD
-0.1 (-0.48%)
After Hours:

This AMPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. AMPH Profitability Analysis

1.1 Basic Checks

  • In the past year AMPH was profitable.
  • In the past year AMPH had a positive cash flow from operations.
  • Each year in the past 5 years AMPH has been profitable.
  • In the past 5 years AMPH always reported a positive cash flow from operatings.
AMPH Yearly Net Income VS EBIT VS OCF VS FCFAMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 6.02%, AMPH belongs to the top of the industry, outperforming 86.91% of the companies in the same industry.
  • The Return On Equity of AMPH (12.44%) is better than 86.91% of its industry peers.
  • With an excellent Return On Invested Capital value of 7.81%, AMPH belongs to the best of the industry, outperforming 86.91% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for AMPH is below the industry average of 13.11%.
Industry RankSector Rank
ROA 6.02%
ROE 12.44%
ROIC 7.81%
ROA(3y)8.41%
ROA(5y)9.36%
ROE(3y)18.58%
ROE(5y)17.39%
ROIC(3y)10.83%
ROIC(5y)11.23%
AMPH Yearly ROA, ROE, ROICAMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20

1.3 Margins

  • AMPH has a better Profit Margin (13.63%) than 86.91% of its industry peers.
  • In the last couple of years the Profit Margin of AMPH has grown nicely.
  • Looking at the Operating Margin, with a value of 19.50%, AMPH belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
  • In the last couple of years the Operating Margin of AMPH has grown nicely.
  • Looking at the Gross Margin, with a value of 49.46%, AMPH is in the better half of the industry, outperforming 63.87% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AMPH has grown nicely.
Industry RankSector Rank
OM 19.5%
PM (TTM) 13.63%
GM 49.46%
OM growth 3Y-3.26%
OM growth 5Y44.05%
PM growth 3Y-9.39%
PM growth 5Y102.5%
GM growth 3Y-0.28%
GM growth 5Y3.84%
AMPH Yearly Profit, Operating, Gross MarginsAMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. AMPH Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMPH is still creating some value.
  • AMPH has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, AMPH has less shares outstanding
  • AMPH has a better debt/assets ratio than last year.
AMPH Yearly Shares OutstandingAMPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
AMPH Yearly Total Debt VS Total AssetsAMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • AMPH has an Altman-Z score of 2.33. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • AMPH's Altman-Z score of 2.33 is fine compared to the rest of the industry. AMPH outperforms 60.21% of its industry peers.
  • The Debt to FCF ratio of AMPH is 5.13, which is a neutral value as it means it would take AMPH, 5.13 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 5.13, AMPH belongs to the best of the industry, outperforming 83.25% of the companies in the same industry.
  • AMPH has a Debt/Equity ratio of 0.77. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
  • AMPH has a Debt to Equity ratio of 0.77. This is in the lower half of the industry: AMPH underperforms 72.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.13
Altman-Z 2.33
ROIC/WACC0.9
WACC8.67%
AMPH Yearly LT Debt VS Equity VS FCFAMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 4.02 indicates that AMPH has no problem at all paying its short term obligations.
  • AMPH's Current ratio of 4.02 is in line compared to the rest of the industry. AMPH outperforms 57.59% of its industry peers.
  • A Quick Ratio of 2.90 indicates that AMPH has no problem at all paying its short term obligations.
  • The Quick ratio of AMPH (2.90) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 2.9
AMPH Yearly Current Assets VS Current LiabilitesAMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. AMPH Growth Analysis

3.1 Past

  • AMPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.80%.
  • The Earnings Per Share has been growing by 38.40% on average over the past years. This is a very strong growth
  • The Revenue has decreased by -1.65% in the past year.
  • The Revenue has been growing by 15.53% on average over the past years. This is quite good.
EPS 1Y (TTM)-15.8%
EPS 3Y18.16%
EPS 5Y38.4%
EPS Q2Q%-20.65%
Revenue 1Y (TTM)-1.65%
Revenue growth 3Y12.99%
Revenue growth 5Y15.53%
Sales Q2Q%-1.83%

3.2 Future

  • Based on estimates for the next years, AMPH will show a decrease in Earnings Per Share. The EPS will decrease by -1.20% on average per year.
  • Based on estimates for the next years, AMPH will show a small growth in Revenue. The Revenue will grow by 4.48% on average per year.
EPS Next Y3.08%
EPS Next 2Y4.66%
EPS Next 3Y4.96%
EPS Next 5Y-1.2%
Revenue Next Year3.78%
Revenue Next 2Y4.21%
Revenue Next 3Y3.87%
Revenue Next 5Y4.48%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMPH Yearly Revenue VS EstimatesAMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
AMPH Yearly EPS VS EstimatesAMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. AMPH Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 6.46, the valuation of AMPH can be described as very cheap.
  • Based on the Price/Earnings ratio, AMPH is valued cheaply inside the industry as 95.29% of the companies are valued more expensively.
  • AMPH's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.79.
  • With a Price/Forward Earnings ratio of 6.27, the valuation of AMPH can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, AMPH is valued cheaply inside the industry as 94.76% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 38.88. AMPH is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 6.46
Fwd PE 6.27
AMPH Price Earnings VS Forward Price EarningsAMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaper than 96.34% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, AMPH is valued cheaply inside the industry as 94.76% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 7.86
EV/EBITDA 5.88
AMPH Per share dataAMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AMPH does not grow enough to justify the current Price/Earnings ratio.
  • AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.1
PEG (5Y)0.17
EPS Next 2Y4.66%
EPS Next 3Y4.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMPH Dividend Analysis

5.1 Amount

  • No dividends for AMPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMPH Fundamentals: All Metrics, Ratios and Statistics

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (4/22/2026, 5:20:00 PM)

After market: 20.89 -0.1 (-0.48%)

20.99

-0.22 (-1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-13
Inst Owners76.54%
Inst Owner Change-0.19%
Ins Owners10.07%
Ins Owner Change4.02%
Market Cap934.68M
Revenue(TTM)719.89M
Net Income(TTM)98.09M
Analysts76.92
Price Target28.56 (36.06%)
Short Float %10.39%
Short Ratio6.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.91%
Min EPS beat(2)-22.4%
Max EPS beat(2)10.58%
EPS beat(4)3
Avg EPS beat(4)1.57%
Min EPS beat(4)-22.4%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)2.84%
EPS beat(12)8
Avg EPS beat(12)9.98%
EPS beat(16)11
Avg EPS beat(16)14.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.97%
Min Revenue beat(2)-5.76%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.93%
Min Revenue beat(4)-5.76%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-1.61%
Revenue beat(12)5
Avg Revenue beat(12)-0.48%
Revenue beat(16)8
Avg Revenue beat(16)-0.12%
PT rev (1m)-11.31%
PT rev (3m)-11.31%
EPS NQ rev (1m)0.26%
EPS NQ rev (3m)-8.72%
EPS NY rev (1m)-0.84%
EPS NY rev (3m)-10.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.47%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-1.08%
Valuation
Industry RankSector Rank
PE 6.46
Fwd PE 6.27
P/S 1.3
P/FCF 7.86
P/OCF 5.99
P/B 1.18
P/tB 4.19
EV/EBITDA 5.88
EPS(TTM)3.25
EY15.48%
EPS(NY)3.35
Fwd EY15.96%
FCF(TTM)2.67
FCFY12.73%
OCF(TTM)3.51
OCFY16.7%
SpS16.17
BVpS17.71
TBVpS5
PEG (NY)2.1
PEG (5Y)0.17
Graham Number35.9908 (71.47%)
Profitability
Industry RankSector Rank
ROA 6.02%
ROE 12.44%
ROCE 9.54%
ROIC 7.81%
ROICexc 9.67%
ROICexgc 18.47%
OM 19.5%
PM (TTM) 13.63%
GM 49.46%
FCFM 16.53%
ROA(3y)8.41%
ROA(5y)9.36%
ROE(3y)18.58%
ROE(5y)17.39%
ROIC(3y)10.83%
ROIC(5y)11.23%
ROICexc(3y)13.25%
ROICexc(5y)14.34%
ROICexgc(3y)28.69%
ROICexgc(5y)24.19%
ROCE(3y)13.23%
ROCE(5y)13.72%
ROICexgc growth 3Y-3.07%
ROICexgc growth 5Y50.2%
ROICexc growth 3Y-19.69%
ROICexc growth 5Y34.74%
OM growth 3Y-3.26%
OM growth 5Y44.05%
PM growth 3Y-9.39%
PM growth 5Y102.5%
GM growth 3Y-0.28%
GM growth 5Y3.84%
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 5.13
Debt/EBITDA 3.09
Cap/Depr 65.49%
Cap/Sales 5.16%
Interest Coverage 6.05
Cash Conversion 79.21%
Profit Quality 121.3%
Current Ratio 4.02
Quick Ratio 2.9
Altman-Z 2.33
F-Score6
WACC8.67%
ROIC/WACC0.9
Cap/Depr(3y)81.11%
Cap/Depr(5y)91.09%
Cap/Sales(3y)5.56%
Cap/Sales(5y)5.56%
Profit Quality(3y)111.67%
Profit Quality(5y)103.97%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.8%
EPS 3Y18.16%
EPS 5Y38.4%
EPS Q2Q%-20.65%
EPS Next Y3.08%
EPS Next 2Y4.66%
EPS Next 3Y4.96%
EPS Next 5Y-1.2%
Revenue 1Y (TTM)-1.65%
Revenue growth 3Y12.99%
Revenue growth 5Y15.53%
Sales Q2Q%-1.83%
Revenue Next Year3.78%
Revenue Next 2Y4.21%
Revenue Next 3Y3.87%
Revenue Next 5Y4.48%
EBIT growth 1Y-31.65%
EBIT growth 3Y9.31%
EBIT growth 5Y66.42%
EBIT Next Year6.27%
EBIT Next 3Y3.07%
EBIT Next 5YN/A
FCF growth 1Y-30.96%
FCF growth 3Y22.23%
FCF growth 5Y38.43%
OCF growth 1Y-26.84%
OCF growth 3Y20.52%
OCF growth 5Y22.21%

AMPHASTAR PHARMACEUTICALS IN / AMPH Fundamental Analysis FAQ

What is the fundamental rating for AMPH stock?

ChartMill assigns a fundamental rating of 6 / 10 to AMPH.


What is the valuation status for AMPH stock?

ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.


What is the profitability of AMPH stock?

AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 8 / 10.


Can you provide the financial health for AMPH stock?

The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 7 / 10.